Edition:
United States

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

29.36EUR
8:54am EDT
Change (% chg)

€-0.12 (-0.41%)
Prev Close
€29.48
Open
€29.48
Day's High
€29.83
Day's Low
€29.36
Volume
2,839
Avg. Vol
7,583
52-wk High
€44.95
52-wk Low
€24.00

Select another date:

Wed, May 3 2017

Carmat buoyed by approval to resume artificial heart trial

Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume a heart implant trial, sending the company's shares more than one fifth higher on Wednesday.

UPDATE 2-Carmat buoyed by approval to resume artificial heart trial

May 3 Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume a heart implant trial, sending the company's shares more than one fifth higher on Wednesday.

Carmat gets approval to resume artificial heart implants trial

May 2 Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume heart implant trials, the company said on Tuesday.

BRIEF-Carmat FY net loss widens to 23 million euros

* Solid cash position of 31.2 million euros ($33.13 million) at December 31, 2016

Carmat withdraws initial request to resume artificial heart implants

Artificial heart maker Carmat said on Monday it had decided to withdraw its initial request to France's national drugs agency (ANSM) to resume trial implantations.

Carmat withdraws initial request to resume artificial heart implants

Feb 6 Artificial heart maker Carmat said on Monday it had decided to withdraw its initial request to France's national drugs agency (ANSM) to resume trial implants.

Carmat shares slump after France halts heart implants

PARIS Shares in artificial heart maker Carmat slumped on Thursday after France's national drugs agency ordered it to suspend further implants following the death of a patient in October.

French drugs agency suspends new Carmat artificial heart implants

PARIS France's national drugs agency said on Wednesday it had ordered artificial heart maker Carmat to suspend further implants after a fifth patient died in October.

Select another date:

More From Around the Web